NWBO (Northwest Biotherapeutics) FCF Margin %: -2,558.30% (As of Mar. 2026)

What is Northwest Biotherapeutics FCF Margin %?

Northwest Biotherapeutics NWBO -0.58% 17 FCF Margin % is -2,558.30% as of Mar. 2026. GuruFocus rates NWBO with a GF Score™ of 17/100. The stock has 5 warning signs investors should review. Among 959 Biotechnology companies, Northwest Biotherapeutics ranks worse than 87.07% on this metric.

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Northwest Biotherapeutics's Free Cash Flow for the three months ended in Mar. 2026 was $-12.64 Mil. Northwest Biotherapeutics's Revenue for the three months ended in Mar. 2026 was $0.49 Mil. Therefore, Northwest Biotherapeutics's FCF Margin % for the quarter that ended in Mar. 2026 was -2,558.30%.

As of today, Northwest Biotherapeutics's current FCF Yield % is -15.89%.

The historical rank and industry rank for Northwest Biotherapeutics's FCF Margin % or its related term are showing as below:

NWBO' s FCF Margin % Range Over the Past 10 Years
Min: -10863.99 Med: -3778.31 Max: -1336.89
Current: -3299.53

During the past 13 years, the highest FCF Margin % of Northwest Biotherapeutics was -1336.89%. The lowest was -10863.99%. And the median was -3778.31%.

NWBO's FCF Margin % is ranked worse than
87.07% of 959 companies
in the Biotechnology industry
Industry Median: -84.65 vs NWBO: -3299.53

Northwest Biotherapeutics FCF Margin % Related Terms

Northwest Biotherapeutics FCF Margin % Historical Data

* Premium members only.

The historical data trend for Northwest Biotherapeutics's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Northwest Biotherapeutics FCF Margin % Chart

Northwest Biotherapeutics Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

FCF Margin %

Get a 7-Day Free Trial

-4,409.35

-3,308.20

-2,954.14

-4,199.06

-3,357.55

Northwest Biotherapeutics Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
FCF Margin %	Get a 7-Day Free Trial															-2,536.27	-5,337.40	-7,047.50	-2,331.70	-2,558.30

NWBO vs PROK, AVIR, IMRX: FCF Margin % Comparison

For the Biotechnology subindustry, Northwest Biotherapeutics's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Northwest Biotherapeutics FCF Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Northwest Biotherapeutics's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Northwest Biotherapeutics's FCF Margin % falls into.

Save Embed

17GF Score

Northwest Biotherapeutics Inc NWBO

FCF Margin % is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Northwest Biotherapeutics FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Northwest Biotherapeutics's FCF Margin for the fiscal year that ended in Dec. 2025 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2025 )	/	Revenue (A: Dec. 2025 )
	=	-46.267	/	1.378
	=	-3,357.55 %

Northwest Biotherapeutics's FCF Margin for the quarter that ended in Mar. 2026 is calculated as

FCF Margin	=	Free Cash Flow (Q: Mar. 2026 )	/	Revenue (Q: Mar. 2026 )
	=	-12.638	/	0.494
	=	-2,558.30 %

Frequently Asked Questions Learn more about FCF Margin % →

What does a FCF Margin % of -2,558.30% mean?

Northwest Biotherapeutics (NWBO) has a FCF Margin % of -2,558.30% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Northwest Biotherapeutics and its competitors. According to the industry distribution chart, Northwest Biotherapeutics ranks #835 out of 959 companies in the Biotechnology industry, placing it in the top 87.1%.

Is Northwest Biotherapeutics' FCF Margin % too high?

Northwest Biotherapeutics' current FCF Margin % is -2,558.30%. Based on the distribution chart, Northwest Biotherapeutics ranks #835 out of 959 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Northwest Biotherapeutics has a GF Score™ of 17/100, reflecting its overall financial health beyond just this single metric.

How does Northwest Biotherapeutics' FCF Margin % compare to PROK and AVIR?

According to the Biotechnology industry distribution chart, Northwest Biotherapeutics ranks #835 out of 959 companies for FCF Margin %. This places Northwest Biotherapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good FCF Margin % for a Biotechnology company?

A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high FCF Margin % mean?

A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Northwest Biotherapeutics and its competitors. Northwest Biotherapeutics's current FCF Margin % is -2,558.30%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Northwest Biotherapeutics stock overvalued right now?

Northwest Biotherapeutics (NWBO) has a current FCF Margin % of -2,558.30%. The current FCF Margin % is -2,558.30%. Northwest Biotherapeutics' overall GF Score™ is 17/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is FCF Margin % calculated?

FCF Margin % is calculated from a company's financial statements. For Northwest Biotherapeutics (NWBO), the current FCF Margin % is -2,558.30% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Northwest Biotherapeutics Business Description

Industry Healthcare Biotechnology

Comparable Companies PROK AVIR IMRX PALI PBYI VSTM GLSI LRMR RGNX ENTA VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY RVMD ASX:CSL ONC XKRX:068270

Other Exchanges NBYB:Germany

Address 4800 Montgomery Lane, Suite 800, Bethesda, MD, USA, 20814

Website https://www.nwbio.com

Northwest Biotherapeutics Inc a biotechnology company focused on developing personalized immune therapies for cancer. The target is a broad range of solid-tumor cancers. The company has a proprietary manufacturing technology, which it uses to produce a personalized vaccine. The product portfolio includes product candidates such as DCVax-L, for patients with brain cancer; DCVax-Direct, direct injection into all types of inoperable solid tumor cancers, and DCVax for late-stage ovarian cancer. DCVax-Prostate, for late-stage prostate cancer, has received clearance from the U.S Food and Drug Administration.

17GF Score

Get the complete analysis for NWBO

FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.19

Price

View NWBO Analysis

See FCF Margin % data for all stocks →